Selecta To Perform Preclinical Malaria Vaccine Work For SAIC
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech will combine its SVP platform technology with a SAIC-developed antigen to try to find the key to treating malaria.
You may also be interested in...
Deals of the Week: Sanofi/Selecta, Evotec/Probiodrug, Nestle/Chi-Med…
European economists meeting in London discuss drug innovation’s costs to the larger health system, research funding sources, and “sin taxes.”
Sanofi And Selecta To Partner On Immunotherapies For Life-Threatening Allergies
Vaccine and immunotherapy-focused Selecta, up to now focused on grants for funding, signs its first big pharma partner around targeted, antigen-specific programs for undisclosed allergies.
To Russia, With Love: Selecta, BIND To Create Subsidiaries In Financing Deals With Rusnano
The U.S. biotechs, which are independent but share founders and investors, raise a combined $94.5 million from the Russian sovereign fund and U.S. venture firms.